In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

Mu opioid receptor (MOPr) agonists are well-known and frequently used clinical analgesics but are also rewarding due to their highly addictive and often abusive properties. This may lead to opioid use disorder (OUD) a disorder that effects millions of people worldwide. Therefore, novel compounds are...

Full description

Bibliographic Details
Main Authors: Alex S. Lee, Suchi Tiwari, Isabel Bishop, Vartan Matossian, Nicole Romaneschi, Takahiro Miyazaki, Laurie VanderVeen, Jonathan Zalevsky, Kathryn DeFea, Catherine M. Cahill, Wendy M. Walwyn
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pain Research
Subjects:
NKTR-181
opioid use disorder
mu opioid receptor
analgesia
pre-clinical
abuse liability
Online Access:https://www.frontiersin.org/articles/10.3389/fpain.2021.695962/full

Internet

https://www.frontiersin.org/articles/10.3389/fpain.2021.695962/full

Similar Items